Gain Therapeutics Inc. (GANX)
| Sector: | NA |
| Super Investor Stats: | |
| Ownership count: | 1 |
| Ownership rank: | 667 |
| % of all portfolios: | 0.001% |
| |
| Total insider Buys/Sells last 6 months: |
| Transactions | Total |
| Buys |
4 |
$85,154 |
| Sells |
0 |
$0 |
Open Market Insider Buys
| Date Filed |
Reporting Name |
Relationship |
Trans. Date |
Shares |
Price $ |
Total Value $ |
| 12 Aug 2024 |
MACK GENE |
CFO and Interim CEO |
09 Aug 2024 |
14,400 |
1.01 |
14,544 |
| 12 Aug 2024 |
ISLAM KHALID |
Executive Chairman |
09 Aug 2024 |
50,000 |
1.00 |
49,940 |
| 01 Jul 2024 |
RICHMAN ERIC I |
Director |
01 Jul 2024 |
5,000 |
1.23 |
6,150 |
| 01 Jul 2024 |
RICHMAN ERIC I |
Director |
01 Jul 2024 |
12,000 |
1.21 |
14,520 |
| 01 Apr 2024 |
RILEY JEFFREY SCOTT |
Director |
28 Mar 2024 |
30,000 |
3.86 |
115,770 |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.
P = Preferred Stock